A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2018
At a glance
- Drugs Influenza A virus vaccine H7N9 (Primary) ; AS03A
- Indications Influenza A virus H7N9 subtype
- Focus Adverse reactions; Pharmacodynamics
- 15 Mar 2018 According to the National Institutes of Health media release, Lisa A. Jackson is the principal investigator for this trial.
- 16 Nov 2017 Status changed from not yet recruiting to recruiting.
- 19 Oct 2017 New trial record